PPARA and experimental autoimmune encephalomyelitis: Several studies have confirmed the inhibitory effect of PPAR agonists in immune and inflammatory responses, especially in the central nervous system inflammation and demyelination in experimental autoimmune encephalomyelitis (127–130).